Sandoz Settlement Suggests J&J Buyout Caplyta May Be Tough Nut To Crack
Six More ANDA Filers In Play But Analysts Feel IP Estate May Be Stronger Than Suspected
Sandoz is facing a lengthy wait for its proposed generic version of the touted mega blockbuster Caplyta (lumateperone), while the market waits with anticipation to see if the product’s robust IP can hold up to challenges from an additional six ANDA filers.
